Therapeutic options for cutaneous leishmaniasis

References

• Yanik M., Gurel M. S., Simsek Z., Kati M. The psychological impact of cutaneous leishmaniasis. Clin Exp Dermatol 2004; 29: 464–7
   PubMed Web of Science ®Google Scholar
• World Health Organization. Epidemiological aspects. Control of leishmaniasis. World Health Organ Tech Rep Ser 793. WHO, Geneva 1990; 41–6
   Google Scholar
• Selim M. M., Vlasin Z., Jaroskova L. Leishmaniasis: Currently recommended treatment. Int J Dermatol 1990; 29: 318–21
   PubMedGoogle Scholar
• Weinrauch L., El‐On J. Current therapy of cutaneous leishmaniasis. Int J Dermatol 1987; 26: 567–8
   PubMedGoogle Scholar
• World Health Organization. The leishmaniasis. World Health Organ Tech Rep Ser 701. WHO, Geneva 1984
   Google Scholar
• British Pharmacopeia. HMSO, London 1973; 439–40
   Google Scholar
• Rees P. H., Keating M. I., Kager P. A., Hockmeyer W. T. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 1980; ii: 226–9
   Google Scholar
• Bailly R., Lauwerys R., Buchet J. P., Mahieu P., Konings J. E. Experimental and human studies on antimony metabolism: Their relevance for the biological monitoring of workers exposed to inorganic antimony. Br J Int Med 1991; 48: 93–7
   Google Scholar
• Association of the British Pharmaceutical Industry. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1996–97. Datapharm Publications Ltd, London 1996
   Google Scholar
• Hepburn N. C. Cutaneous leishmaniasis: An overview. J Postgrad Med 2003; 49: 50–4
   PubMedGoogle Scholar
• Rai U. S., Kumar H., Kumar U. Renal dysfunction in patients of kala azar treated with sodium antimony gluconate. J Assoc Physicians India 1994; 42: 383
   PubMedGoogle Scholar
• Mallick B. K. Hypoplasia of bone marrow secondary to sodium antimony gluconate. J Assoc Physicians India 1990; 38: 310–11
   PubMedGoogle Scholar
• Chulay J. D., Spencer H. G., Mugambi M. Electrographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34: 702–9
   PubMed Web of Science ®Google Scholar
• Hendeson A., Jolliffe D. Cardiac effects of sodium stibogluconate. Br J Clin Pharmacol 1985; 19: 73–7
   PubMedGoogle Scholar
• Ashford R. W., Bates P. A. Leishmaniasis in the old world. Topley & Wilson's textbook of microbiology and microbial infections, 9th ed, F. E. G Cox, J Kreier, D Wakelin. Oxford University Press Inc, New York 1998; 5: 260
   Google Scholar
• Hashemi‐Nasab A., Zadeh‐Sharazi H. Visceral leishmaniasis (kala azar) in Fars province, Iran: Study of 130 cases. J Trop Med Hyg 1980; 83: 119–22
   PubMed Web of Science ®Google Scholar
• Navin T., Arana B. A., Arana F. E., Berman J. D., Chajon J. F. Placebo‐controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165: 528–34
   PubMed Web of Science ®Google Scholar
• Ghosh S. Evaluation of sodium stibogluconate in the treatment of cutaneous leishmaniasis in Syria. Curr Med Res Opin 1979; 6: 280–3
   PubMedGoogle Scholar
• Walto B. C., Paulson J. E., Arjona M. A., Peterson C. A. American cutaneous leishmaniasis: Inefficacy of metronidazole in treatment. JAMA 1974; 228: 1256–8
   PubMedGoogle Scholar
• Kern F., Pederson J. K. Leishmaniasis in the United States: A report of ten cases in military personnel. JAMA 1973; 226: 872–4
   PubMedGoogle Scholar
• Ballou W. R., McChain J. R., Gardon D. M., Shanks G. D., Andujar J., Berman J. D., et al. Safety and efficacy of high‐dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987; ii: 13–16
   Google Scholar
• Alkhawaja A. M., Larbi E., Al‐Gindan Y., Abahussein A., Jain S. Treatment of cutaneous leishmaniasis with antimony: Intramuscular versus intralesional administration. Ann Trop Med Parasitol 1997; 91: 899–905
   PubMedGoogle Scholar
• Brycen A. D., Chulay J. D., Mugambi M., Were J. B., Gachihi G., Chunge C. N., et al. Visceral leishmaniasis unresponsive to antimonial drugs: Response to high‐dose sodium stibogluconate or prolonged treatment with pentamidine. Trans R Soc Trop Med Hyg 1985; 79: 705–14
   PubMedGoogle Scholar
• Marsden P. D., Sampaio R. N. R., Carvalho E. M., Veiga J. P. T., Costa J. L. M., Lianos‐Cuentas E. A. High continuous antimony therapy in two patients with unresponsive mucocutaneous leishmaniasis. Am J Trop Med Hyg 1985; 34: 710–13
   PubMed Web of Science ®Google Scholar
• Oster C. N., Chulay J. D., Hendricks L. D., McGarvy P. B., Takafuji E. J., Pamplin C. L 3rd., et al. American cutaneous leishmaniasis: A comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 1985; 34: 856–60
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antimonials. Large scale failure in leishmaniasis ‘alarming’. 1990; 34, TDR News
   Google Scholar
• World Health Organization. Control of leishmaniasis. World Health Organ Tech Rep Ser 793. WHO, Geneva 1990; 66–94
   Google Scholar
• Tallab T. M., Bahamdam K. A., Mirdad S., Johargi H., Mourad M. M., Ibrahim K., et al. Cutaneous leishmaniasis: Schedule for intralesional treatment with sodium stibogluconate. Int J Dermatol 1996; 35: 594–7
   PubMed Web of Science ®Google Scholar
• Sharquie K. E., Al‐Talib K. K., Chu A. C. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988; 119: 53–7
   PubMed Web of Science ®Google Scholar
• Kellum R. E. Treatment of cutaneous leishmaniasis with an intralesional antimony drug (Pentostam). J Am Acad Dermatol 1986; 15: 620–2
   PubMed Web of Science ®Google Scholar
• Sharma R. C., Mahajan V. K., Sharma N. L., Sharma A. A new focus of cutaneous leishmaniasis in Himachal Pradesh (India). Indian J Dermatol Venereol Leprol 2003; 69: 170–2
   PubMedGoogle Scholar
• Sharma N. L., Mahajan V. K., Kanga A., Sood A., Katoch V. M., Mauricio I., et al. Localized cutaneous leishmaniasis due to Leishmania donovani and Leishmania tropica: A preliminary finding of the study of 161 new cases from a new focus in Himachal Pradesh, India. Am J Trop Med Hyg 2005; 72: 819–24
   PubMed Web of Science ®Google Scholar
• Kubba R., Al‐Gindan Y., El‐Hassan A. M., Omer A. H. S. Ketoconazole in cutaneous leishmaniasis: Results of a pilot study. Saudi Med J 1986; 7: 596–604
   Google Scholar
• Berman J. D. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684–703
   PubMed Web of Science ®Google Scholar
• Berman J. D., Holz G. G., Beach D. H. Effects of ketoconazole on growth and sterol biosynthesis of Leishmania maxicana promastigotes in culture. Mol Biochem Parasitol 1984; 12: 1–13
   PubMed Web of Science ®Google Scholar
• Brenner S. Topical treatment with imidazoles for cutaneous leishmaniasis. Isr J Med Sci 1985; 15: 620–2
   Google Scholar
• Larbi E. M., Alkhawajah A. M., Al‐Gindan Y., Jain S., Abahusain A., Al‐Zayer A. A randomized, double‐blind clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the Eastern Province of Saudi Arabia. Am J Trop Med Hyg 1995; 52: 166–8
   PubMed Web of Science ®Google Scholar
• Abahusain A., Larbi E. B., Alkhawajah A., Al‐Gindan Y., Jain S. Evaluation of topical ketoconazole in cutaneous leishmaniasis. East Afr Med J 1992; 69: 14–19
   PubMedGoogle Scholar
• Weinrauch L., Livshin R., El‐On J. Cutaneous leishmaniasis treatment with ketoconazole. Cutis 1983; 32: 288–9
   PubMed Web of Science ®Google Scholar
• Urcuyo F. G., Zaias N. Oral ketoconazole in the treatment of leishmaniasis. Int J Dermatol 1982; 21: 414–16
   PubMed Web of Science ®Google Scholar
• Jollife D. S. Cutaneous leishmaniasis from Belize: Treatment with ketoconazole. Clin Exp Dermatol 1986; 11: 62–8
   PubMedGoogle Scholar
• Macnair A. L., Gascoigne E., Heap J. Hepatitis and ketoconazole therapy. Br Med J 1981; 283: 1058–60
   PubMed Web of Science ®Google Scholar
• Unnithan M. L., Pillai S. M. S., Vijayadharan M., Sarojini M. Two cases of cutaneous leishmaniasis seen in Trvandrum. Indian J Dermatol Venereol Leprol 1988; 54: 161–2
   PubMedGoogle Scholar
• DeBeule K., Couwenberg G. The treatment of cutaneous leishmaniasis with ketoconazole and itraconazole. Recent advances in chemotherapy, Antimicrobial (Section 2), E Rubinstein, E Adam. Lewin‐Epstein Ltd, Jerusalem 1989; 612.1–612.2
   Google Scholar
• Vanden‐Enden E., Campel A., Stevens A., Vandeghinote N., LeRay D., Gigase P., et al. Treatment of cutaneous leishmaniasis with oral itraconazole. Int J Dermatol 1994; 33: 285–6
   PubMedGoogle Scholar
• Momeni A. Z., Jalayer T., Emamjomeh M., et al. Treatment of cutaneous leishmaniasis with itraconazole. Arch Dermatol 1996; 132: 784–6
   PubMedGoogle Scholar
• Alrajhi A. A., Ibrahim E. A., DeVol E. B., Khairat M., Faris R. M., Maguire J. H. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891–5
   PubMed Web of Science ®Google Scholar
• Gonzáles U. Fluconazole for cutaneous leishmaniasis: Looking for a better treatment. Arch Dermatol 2002; 138: 1604–6
   PubMedGoogle Scholar
• Beltran H. F., Gutierrez F. M., Biagi F. F. Treatment of Mexican cutaneous leishmaniasis with metronidazole. Bull Soc Pathol Exot 1967; 70: 61
   Google Scholar
• Long P. Cutaneous leishmaniasis treatment with metronidazole. JAMA 1973; 223: 1378–9
   PubMedGoogle Scholar
• Bharija S. C., Kanwar A. J., Belhaj M. S. Cutaneous leishmaniasis in eastern Libya. Indian J Dermatol Venereol Leprol 1987; 53: 241–3
   PubMedGoogle Scholar
• Verma K. C., Bhargava N. C., Joshi R. K. Cutaneous leishmaniasis. Indian J Dermatol Venereol Leprol 1979; 45: 341–3
   PubMedGoogle Scholar
• Wahba A., Cohen C. Cutaneous leishmaniasis: Inefficacy of treatment with metronidazole. Arch Dermatol 1979; 113: 1299
   Google Scholar
• Pederson J. K., Sawicki S. Metronidazole therapy for cutaneous leishmaniasis. Arch Dermatol 1975; 111: 1343–4
   PubMedGoogle Scholar
• Belehu A., Naffs B., Touw‐langendijk E. Failure of metronidazole treatment in Ethiopian mucocutaneous leishmaniasis. Br J Dermatol 1978; 99: 421–2
   PubMedGoogle Scholar
• Selim M. M., Kandil E. Rifampicin in treatment of cutaneous leishmaniasis. J Kuwait Med Res 1972; 6: 159–66
   Google Scholar
• Vasquiz F. R. Rifampicin in leishmaniasis. Arch Dermatol 1977; 113: 1610–11
   Google Scholar
• Muhammed K., Narayani K., Arvindan K. P. Indigenous cutaneous leishmaniasis. Indian J Dermatol Venereol Leprol 1990; 56: 228–9
   Google Scholar
• Gupta R., Pasricha J. S. Evaluation of rifampicin for cutaneous leishmaniasis. Indian J Dermatol Venereol Leprol 1984; 50: 131–3
   Google Scholar
• Khatri M. L., Shafi M., Mosadiq M. Cutaneous leishmaniasis in Tripoli: A study of 36 cases. Indian J Dermatol Venereol Leprol 1984; 50: 137–41
   Google Scholar
• White S. W., Hendricks L. D., Chulay J. D. Leishmaniasis: A case history and treatment failure with rifampicin. Arch Dermatol 1980; 116: 620–1
   PubMedGoogle Scholar
• Livshin R., El‐On J., Weinrauch L., Grenblatt C. L., Even‐Paz Z. Therapeutic effect of rifampicin and isoniazid against Leishmania tropica major. Int J Dermatol 1983; 22: 61
   PubMedGoogle Scholar
• Pareek S. Combination therapy of sodium stibogluconate and rifampicin in cutaneous leishmaniasis. Int J Dermatol 1984; 23: 70–1
   PubMed Web of Science ®Google Scholar
• Dogra J., Lal B. B., Misra S. N. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol 1986; 25: 398–400
   PubMed Web of Science ®Google Scholar
• Dogra J., Lal B. B., Misra S. N. Cutaneous leishmaniasis: Therapeutic efficacy of dapsone in the commonly existing subtypes. Indian J Dermatol Venereol Leprol 1989; 55: 375–7
   PubMedGoogle Scholar
• Singh K. K., Lal B. B., Rajvanshi P., Mukhija R. D., Mohan L., Chandra S., et al. Further evaluation of dapsone in cutaneous leishmaniasis. Indian J Dermatol Venereol Leprol 1991; 57: 96–7
   Google Scholar
• McMillan B. The inhibition of leptomonads of the genus Leishmania in culture by antifungal antibiotics. Ann Trop Med Parasitol 1960; 54: 293–9
   Google Scholar
• Cappuccino E. F., Stauber L. A. Some compounds active against experimental visceral leishmaniasis. Proc Soc Exp Biol Med 1959; 101: 742–4
   PubMedGoogle Scholar
• Sampaio S. A., Castro R. M., Dillon N. L., Martins J. E. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: Report of 70 cases. Int J Dermatol 1971; 10: 178–81
   Google Scholar
• Croft S. L., Seifert K., Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006; 123: 399–410
   PubMed Web of Science ®Google Scholar
• Bryceson A. D. M. Leishmaniasis. Cecil's textbook of medicine, J. B Wyngaarden, L. H Jr Smith. Churchill Livingstone, Edinburgh 1980; 815–18
   Google Scholar
• Chong H. Oriental sore. A look at trends in and approaches to the treatment of leishmaniasis. Int J Dermatol 1986; 25: 615–23
   PubMedGoogle Scholar
• Ganor S. Treatment of leishmaniasis recidivans with local injections of amphotericin B. Dermatol Int 1967; 6: 141–3
   PubMedGoogle Scholar
• Zvulunov A., Cagnano E., Frankenburg S., Barenholtz Y., Vardy D. Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B. Pediatr Infect Dis J 2003; 22: 567–9
   PubMed Web of Science ®Google Scholar
• El‐On J., Jacobs G. P., Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988; 4: 76–81
   PubMedGoogle Scholar
• El‐On J., Messer G. Leishmania major: Antileishmanial activity of methylbenzethonium chloride. Am J Trop Med Hyg 1986; 35: 1110–16
   PubMed Web of Science ®Google Scholar
• El‐Safi S. H., Murphy A. G., Bryceson A. D. M., Neal R. A. A double‐blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans R Soc Trop Med Hyg 1990; 84: 690–1
   PubMed Web of Science ®Google Scholar
• Moosavi Z., Nakhli A., Rassaii S. Comparing the efficacy of topical paromomycin with intralesional megalumine antimoniate for cutaneous leishmaniasis. Int J Dermatol 2004; 44: 1054–5
   Google Scholar
• Ozgoztasi O., Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol 1997; 36: 61–3
   PubMed Web of Science ®Google Scholar
• Henriksen T. H., Lende S. Treatment of cutaneous leishmaniasis with chlorpromazine ointment. Lancet 1983; i: 126
   Google Scholar
• Pearson R. D., Manian A. A., Harcus J. L., Hall D., Hewlett E. L. Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donovani. Science 1982; 217: 369–71
   PubMed Web of Science ®Google Scholar
• Ziberstein D., Dwyer D. M. Antidepressants cause lethal disruption of membrane in the human protozoan parasite Leishmania. Science 1984; 226: 977–9
   PubMedGoogle Scholar
• Brenner S. Topical treatment with imidazoles for cutaneous leishmaniasis. Isr J Med Sci 1985; 21: 163–4
   PubMedGoogle Scholar
• Momeni A. Z., Aminjavaheri M., Omidghaemi M. R. Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatol Treat 2003; 14: 26–9
   PubMedGoogle Scholar
• Arevalo I., Ward B., Miller R., Meng T. C., Najar E., Alvarez E., et al. Successful treatment of drug‐resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33: 1847–51
   PubMed Web of Science ®Google Scholar
• Seeberger J., Daoud S., Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol 2003; 42: 576–9
   PubMed Web of Science ®Google Scholar
• Hoare C. A. Early discoveries regarding the parasites of oriental sore. Trans R Soc Trop Med Hyg 1938; 32: 67–92
   Google Scholar
• Currie M. A. Treatment of cutaneous leishmaniasis by curretage. Br Med J 1983; 287: 1105–6
   PubMedGoogle Scholar
• Azab A. S., Kamal M. S., El‐Hagar M. S., Metawaa B. A., Hindway D. S. Early surgical treatment of cutaneous leishmaniasis. J Dermatol Surg Oncol 1983; 9: 1007–12
   PubMedGoogle Scholar
• Berman J. D., Nera F. K. Effect of temperature on multiplication of leishmania amastigotes within human monocyte‐derived macrophages in vitro. Am J Trop Med Hyg 1981; 149: 302–18
   Google Scholar
• Junaid A. J. N. Treatment of cutaneous leishmaniasis with infra‐red heat. Int J Dermatol 1986; 25: 470–2
   PubMed Web of Science ®Google Scholar
• Mutinga M. J., Mingola E. N. Alternate treatment of cutaneous leishmaniasis. East Afr Med J 1974; 51: 68–78
   PubMedGoogle Scholar
• Bassiony A., El‐Mashad M., Talaat M., Kutty K., Metaawa B. Cryotherapy in cutaneous leishmaniasis. Br J Dermatol 1982; 107: 467–74
   PubMedGoogle Scholar
• Panagiotopoulos A., Stavropoulos P. G., Hasapi V., Papakonstantinou A‐M., Petridis A. Treatment of cutaneous leishmaniasis with cryosurgery. Int J Dermatol 2005; 44: 749–52
   PubMed Web of Science ®Google Scholar
• Leibovice V., Arun H. Cryotherapy in acute cutaneous leishmaniasis. Int J Dermatol 1986; 25: 473–5
   PubMedGoogle Scholar
• Al‐Gindan Y., Kubba R., El‐Hassan A. M., Omar A. H. S., Kutty N. K., Saeed M. B. Dissemination in cutaneous leishmaniasis: Lymph node involvement. Int J Dermatol 1989; 28: 248–54
   PubMed Web of Science ®Google Scholar
• D'Oliveira A Jr., Machado P. R. L., Carvalho E. M. Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis. Int J Dermatol 1997; 36: 938–46
   PubMedGoogle Scholar
• Soyuer U., Aktas E. Intralesional bleomycin therapy for leishmaniasis cutis. Arch Dermatol 1988; 124: 1571
   PubMedGoogle Scholar
• Guerra M. F., Marsden P. D., Cuba C. C., Barreto A. C. Further trials of nifurtimox in mucocutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1981; 75: 335–7
   PubMedGoogle Scholar
• Sadeghian G., Nilforoushzadeh M. A. Effect of combination therapy with systemic glucantine and pentoxifyllin in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45: 819–21
   PubMed Web of Science ®Google Scholar
• Bahamdan K. A., Tallab T. M., Johargi H., Mourad M. M., Ibrahim K., El‐Sherbini A. H., et al. Terbinafine in the treatment of cutaneous leishmaniasis: A pilot study. Int J Dermatol 1997; 36: 59–60
   PubMed Web of Science ®Google Scholar
• Frezard F., Michalick M. S., Soares C. F., Demicheli C. Novel methods for the encapsulation of meglumine antimoniate into liposomes. Braz J Med Biol Res 2000; 33: 841–6
   PubMed Web of Science ®Google Scholar
• Pal S., Ravindaran R., Ali N. Combination therapy using sodium antimony gluconate in stearylamine‐bearing liposomes against established and chronic Leishmania donovani infection in BALB/C mice. Antimicrob Agents Chemother 2004; 48: 3591–3
   PubMed Web of Science ®Google Scholar
• Alkhawajah A. Recent trends in the treatment of cutaneous leishmaniasis. Ann Saudi Med 2000; 185: 4–7
   Google Scholar
• Squires K. A., Rosenkaimer F., Sherwood J. A., Forni A. L., Were J. B., Murray H. W. Immunochemotherapy for visceral leishmaniasis: A controlled pilot trial of antimony versus antimony plus interferon gamma. Am J Trop Med Hyg 1993; 48: 666–9
   PubMed Web of Science ®Google Scholar
• Markled M., Rifaat M., Azab M., Makhlouf S., El‐Missery A., Khalil N. Determination of healing response by immunostimulant therapy (levamizole) in cutaneous leishmaniasis. Chemioterapia 1987; 6((suppl 2))214–16
   PubMedGoogle Scholar
• Karkeuoglu N., Tandogdu R. Interferon gamma therapy for cutaneous leishmaniasis. Arch Dermatol 1990; 126: 831–2
   PubMedGoogle Scholar
• Sharifi I., FeKri A. R., Aflatonian M. R., Khamesipour A., Nadim A., Mousavi M. R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351: 1540–3
   PubMed Web of Science ®Google Scholar
• Machado‐Pinto J., Pinto J., daCosta C. A., Genaro A., Marques M. J., Modabber F., et al. Immunotherapy for cutaneous leishmanisis: A controlled trial using killed Leishmania amazonensis vaccine plus antimonial. Int J Dermatol 2002; 41: 73–8
   PubMed Web of Science ®Google Scholar
• Hansjorg E. Miltefosine for visceral leishmaniasis. N Engl J Med 2000; 342: 894–5
   PubMedGoogle Scholar
• Sundar S., Gupta L. B., Makharia M. K., Murray H. W., Singh M. K., Voss A., et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999; 93: 589–97
   PubMed Web of Science ®Google Scholar
• Gangneux J. P. Treatment of visceral leishmaniasis: Recent modalities. Presse Med 1999; 28: 2057–66
   PubMedGoogle Scholar
• Jha T. K., Sundar S., Thakur C. P., Bachmann P., Karbwamg J., Fischer C., et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795–800
   PubMed Web of Science ®Google Scholar
• Zerpa O., Blanco B., Kannee C., Ulrich M., Sindermann H., Engel J., et al. Treatment of cutaneous leishmaniasis with miltefosine: A case report. Int J Dermatol 2006; 45: 751–3
   PubMed Web of Science ®Google Scholar
• Thakur C. P., Sinha P. K., Singh K. R., Hassan S. M., Narain S. Miltefosine in a case of visceral leishmaniasis and rising incidence of this disease in India. Trans R Trop Med Hyg 2000; 94: 696–7
   PubMed Web of Science ®Google Scholar
• Soto J., Toledo J., Gutierrez P., Nicolls R. S., Padilla J., Engel J., et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001; 33: e57–61
   PubMedGoogle Scholar
• Schmidt‐Ott R., Klenner T., Overath P., Aebischer T. Topical treatment with hexadecylphosphocholine (miltex) efficiently reduces parasite in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93: 85–90
   PubMed Web of Science ®Google Scholar
• Murray H. W. Suppression of post treatment recurrence of experimental visceral leishmaniasis in T‐cell‐deficient mice by oral miltefosine. Antimicrob Agents Chemother 2000; 44: 3235–6
   PubMed Web of Science ®Google Scholar
• Beckers T., Voegeli R., Hilgard P. Molecular and cellular effects of hexadecylophospholine (miltefosine) in human myeloid leukemic cell lines. Eur J Cancer 1994; 30: 2143–50
   Google Scholar
• Santa‐Rita R. M., Henriques‐Pons A., Barbosa H. S., DeCastro L. S. Effects of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J Antimicrob Chemother 2004; 54: 704–10
   PubMed Web of Science ®Google Scholar
• Khalil E. A., El Hassan A. M., Zijlstra E. F., Mukhtar M. M., Ghalib H. W., Musa B., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A random, double‐blind, BCG‐controlled trial in Sudan. Lancet 2000; 356: 1565–9
   PubMed Web of Science ®Google Scholar
• Stobie L., Gurunathan S., Prussin C., Sacks D. L., Glaichenhans N., Wu Cy., Seder R. A. The role of antigen and IL‐12 in sustaining Th1 memory cells in vivo: IL‐12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infection parasite challenge. Proc Natl Acad Sci U S A 2000; 97: 8427–32
   PubMed Web of Science ®Google Scholar
• Rhee E. G., Mendez S., Shah J. A., Wu Cy., Kirman J. R., Turon T. N., et al. Vaccination with heat‐killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long‐term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 2002; 195: 1565–73
   PubMed Web of Science ®Google Scholar
• Davies C. R., Kaye P., Croft S. L., Sundar S. Leishmaniasis: New approaches to disease control. Br Med J 2003; 326: 377–82
   PubMed Web of Science ®Google Scholar
• Reyburn H., Ashford R., Mohsen M., Hewitt S., Rowland M. A randomized controlled trial of insecticide treated bednets and chaddars or topsheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans R Soc Trop Med Hyg 2000; 94: 361–6
   PubMed Web of Science ®Google Scholar
• Davies C. R., Llanos‐Cuentas E. A., Campos P., Monges J., Leon E., Canales J. Spraying houses in the Peruvian Andes with lambda‐cyhalothrin protects residents against cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94: 631–6
   PubMed Web of Science ®Google Scholar
• Lane R. P. Phlebotomine sandflies. Manson's tropical diseases, P Manson, G. C Cook, A Zumla. Saunders, London 2003; 1733–41, 21st ed
   Google Scholar
• Kroeger A., Avila E. V., Morison L. Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: Cluster randomized trial. Br Med J 2002; 325: 810–13
   PubMedGoogle Scholar